JPS64930B2 - - Google Patents

Info

Publication number: JPS64930B2
Authority: JP; Japan
Prior art keywords: culture; cyclodextrin; pertussis; fraction; amount
Prior art date: 1983-03-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

JP58054680A

Other languages

English (en)

Japanese (ja)

Other versions

JPS59181222A (ja

Inventor

Akihiro Ginnaga

Hiroshi Kiba

Susumu Sakuma

Hisashi Kitagawa

Akira Yamada

Yoji Suzuki

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Teijin Ltd

Original Assignee

Teijin Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-03-30

Filing date

1983-03-30

Publication date

1989-01-10

1983-03-30 Application filed by Teijin Ltd filed Critical Teijin Ltd

1983-03-30 Priority to JP58054680A priority Critical patent/JPS59181222A/ja

1984-03-26 Priority to CA000450495A priority patent/CA1213234A/en

1984-03-29 Priority to AT84103504T priority patent/ATE65028T1/de

1984-03-29 Priority to DE8484103504T priority patent/DE3484778D1/de

1984-03-29 Priority to AU26230/84A priority patent/AU564634B2/en

1984-03-29 Priority to KR1019840001645A priority patent/KR900007658B1/ko

1984-03-29 Priority to EP84103504A priority patent/EP0121249B1/de

1984-03-29 Priority to SU843728854A priority patent/SU1447266A3/ru

1984-03-29 Priority to ES531112A priority patent/ES531112A0/es

1984-10-15 Publication of JPS59181222A publication Critical patent/JPS59181222A/ja

1986-06-16 Priority to US06/874,670 priority patent/US4687738A/en

1989-01-10 Publication of JPS64930B2 publication Critical patent/JPS64930B2/ja

Status Granted legal-status Critical Current

Links

238000004519 manufacturing process Methods 0.000 claims description 26
230000012010 growth Effects 0.000 claims description 22
238000005273 aeration Methods 0.000 claims description 20
230000001580 bacterial effect Effects 0.000 claims description 20
241000588832 Bordetella pertussis Species 0.000 claims description 18
238000000034 method Methods 0.000 claims description 16
229920000858 Cyclodextrin Polymers 0.000 claims description 13
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 10
208000015181 infectious disease Diseases 0.000 claims description 9
239000007788 liquid Substances 0.000 claims description 9
239000000427 antigen Substances 0.000 claims description 8
102000036639 antigens Human genes 0.000 claims description 8
108091007433 antigens Proteins 0.000 claims description 8
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 8
HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims description 6
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
229910052760 oxygen Inorganic materials 0.000 claims description 6
239000001301 oxygen Substances 0.000 claims description 6
230000003254 anti-foaming effect Effects 0.000 claims description 5
239000002518 antifoaming agent Substances 0.000 claims description 5
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 4
239000000126 substance Substances 0.000 claims description 4
230000005526 G1 to G0 transition Effects 0.000 claims description 3
230000003698 anagen phase Effects 0.000 claims description 3
GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 3
239000001116 FEMA 4028 Substances 0.000 claims description 2
108010024636 Glutathione Proteins 0.000 claims description 2
239000002253 acid Substances 0.000 claims description 2
229960005070 ascorbic acid Drugs 0.000 claims description 2
235000010323 ascorbic acid Nutrition 0.000 claims description 2
239000011668 ascorbic acid Substances 0.000 claims description 2
235000011175 beta-cyclodextrine Nutrition 0.000 claims description 2
229960004853 betadex Drugs 0.000 claims description 2
229940080345 gamma-cyclodextrin Drugs 0.000 claims description 2
229960003180 glutathione Drugs 0.000 claims description 2
229920001450 Alpha-Cyclodextrin Polymers 0.000 claims 1
229940043377 alpha-cyclodextrin Drugs 0.000 claims 1
239000002609 medium Substances 0.000 description 30
241000894006 Bacteria Species 0.000 description 25
201000005702 Pertussis Diseases 0.000 description 14
238000013019 agitation Methods 0.000 description 13
238000003756 stirring Methods 0.000 description 11
229960005486 vaccine Drugs 0.000 description 11
239000000243 solution Substances 0.000 description 10
230000000052 comparative effect Effects 0.000 description 9
229940066827 pertussis vaccine Drugs 0.000 description 6
238000012258 culturing Methods 0.000 description 5
230000000694 effects Effects 0.000 description 5
210000004027 cell Anatomy 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000003068 static effect Effects 0.000 description 3
239000003053 toxin Substances 0.000 description 3
231100000765 toxin Toxicity 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
241000233866 Fungi Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 2
229940099552 hyaluronan Drugs 0.000 description 2
229920002674 hyaluronan Polymers 0.000 description 2
238000011081 inoculation Methods 0.000 description 2
239000002054 inoculum Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
238000002255 vaccination Methods 0.000 description 2
208000035473 Communicable disease Diseases 0.000 description 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
101710154643 Filamentous hemagglutinin Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
101710154606 Hemagglutinin Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
101710194807 Protective antigen Proteins 0.000 description 1
101710176177 Protein A56 Proteins 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
206010043376 Tetanus Diseases 0.000 description 1
239000000654 additive Substances 0.000 description 1
238000009098 adjuvant therapy Methods 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
229960001212 bacterial vaccine Drugs 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000012136 culture method Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
206010013023 diphtheria Diseases 0.000 description 1
229960003983 diphtheria toxoid Drugs 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
-1 fatty acid ester Chemical class 0.000 description 1
239000006260 foam Substances 0.000 description 1
238000005187 foaming Methods 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
230000035931 haemagglutination Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
239000000185 hemagglutinin Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
229940031551 inactivated vaccine Drugs 0.000 description 1
238000009776 industrial production Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
244000005700 microbiome Species 0.000 description 1
239000000203 mixture Substances 0.000 description 1
231100000957 no side effect Toxicity 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000005180 public health Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229960000814 tetanus toxoid Drugs 0.000 description 1
238000009423 ventilation Methods 0.000 description 1

Landscapes

Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

JP58054680A 1983-03-30 1983-03-30 百日ぜき菌の感染防御抗原ｈａ画分の製造方法 Granted JPS59181222A (ja)

Priority Applications (10)

Application Number	Priority Date	Filing Date	Title
JP58054680A JPS59181222A (ja)	1983-03-30	1983-03-30	百日ぜき菌の感染防御抗原ｈａ画分の製造方法
CA000450495A CA1213234A (en)	1983-03-30	1984-03-26	Method for the production of ha fraction containing protective antigens of bordetella pertussis and pertussis vaccine
KR1019840001645A KR900007658B1 (ko)	1983-03-30	1984-03-29	백일해균 예방항원을 함유하는 ha 유분(留分)과 백일해 왁진의 제조방법
DE8484103504T DE3484778D1 (de)	1983-03-30	1984-03-29	Verfahren zur herstellung der bordetella-pertussis-schutzantigene enthaltenden ha fraktion und keuchhustenvakzin.
AU26230/84A AU564634B2 (en)	1983-03-30	1984-03-29	Method for production of ha fraction containing protective antigens
AT84103504T ATE65028T1 (de)	1983-03-30	1984-03-29	Verfahren zur herstellung der bordetellapertussis-schutzantigene enthaltenden ha fraktion und keuchhustenvakzin.
EP84103504A EP0121249B1 (de)	1983-03-30	1984-03-29	Verfahren zur Herstellung der Bordetella-Pertussis-Schutzantigene enthaltenden HA Fraktion und Keuchhustenvakzin
SU843728854A SU1447266A3 (ru)	1983-03-30	1984-03-29	Способ получени фракции НА, содержащей защитный антиген ВоRDетеLLа реRтUSSIS
ES531112A ES531112A0 (es)	1983-03-30	1984-03-29	Un metodo para la produccion de una fraccion ha que contiene antigenos protectores de bordetella pertussis
US06/874,670 US4687738A (en)	1983-03-30	1986-06-16	Method for the production of HA fraction containing protective antigens of Bordetella pertussis and pertussis vaccine

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP58054680A JPS59181222A (ja)	1983-03-30	1983-03-30	百日ぜき菌の感染防御抗原ｈａ画分の製造方法

Publications (2)

Publication Number	Publication Date
JPS59181222A JPS59181222A (ja)	1984-10-15
JPS64930B2 true JPS64930B2 (de)	1989-01-10

Family

ID=12977497

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP58054680A Granted JPS59181222A (ja)	1983-03-30	1983-03-30	百日ぜき菌の感染防御抗原ｈａ画分の製造方法

Country Status (2)

Country	Link
JP (1)	JPS59181222A (de)
SU (1)	SU1447266A3 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2148412C1 (ru) *	1999-08-06	2000-05-10	Москаленко Екатерина Петровна	Способ получения протективного коклюшного антигена
BR112014017898B1 (pt) *	2012-02-01	2021-10-13	Glaxosmithkline Biologicals S.A.	Processo de fermentação

1983
- 1983-03-30 JP JP58054680A patent/JPS59181222A/ja active Granted
1984
- 1984-03-29 SU SU843728854A patent/SU1447266A3/ru active

Also Published As

Publication number	Publication date
JPS59181222A (ja)	1984-10-15
SU1447266A3 (ru)	1988-12-23

Publication	Publication Date	Title
EP0121249B1 (de)	1991-07-10	Verfahren zur Herstellung der Bordetella-Pertussis-Schutzantigene enthaltenden HA Fraktion und Keuchhustenvakzin
JPH06505146A (ja)	1994-06-16	ヒアルロン酸の製造
US4144129A (en)	1979-03-13	Cholesteroloxidase and method for its production from microorganisms
CN109536460A (zh)	2019-03-29	一种cv-a10病毒毒种及其人用灭活疫苗
US5550051A (en)	1996-08-27	Avian embryo cell aggregate biomass for producing virus/virus antigen and method for producing virus/virus antigen
KR101617464B1 (ko)	2016-05-02	Ｉｐｖ―ｄｐｔ 백신
JP3724821B2 (ja)	2005-12-07	Ａ型肝炎（ｈａｖ）の抗原およびワクチンの製造方法
JPS64930B2 (de)	1989-01-10
JPS64931B2 (de)	1989-01-10
CN114990075A (zh)	2022-09-02	一株可适用于人用疫苗细胞基质培养的柯萨奇病毒a组10型疫苗株及其应用
JP4391114B2 (ja)	2009-12-24	酵素の大量生産法
JPH06503802A (ja)	1994-04-28	酵素処理されたｂｃｇワクチンおよびその製造方法
EP0238407A1 (de)	1987-09-23	Industrielles Verfahren zur Herstellung ribosomaler Impfstoffe und die so erhaltenen ribosomalen Impfstoffe
JP2006528486A (ja)	2006-12-21	カンジダトロピカリスｃｊ−ｆｉｄ菌株（ｋｃｔｃ１０４５７ｂｐ）およびそれを利用したキシリトールの生産方法
RU2287343C1 (ru)	2006-11-20	Способ получения антирабической вакцины
CN111662881B (zh)	2021-06-18	新型冠状病毒Vero细胞灭活疫苗病毒液及其生产方法
JP2593147B2 (ja)	1997-03-26	感染防御抗原産生菌用培地組成物
WO2007135941A1 (ja)	2007-11-29	酢酸菌型セラミドの製造方法
JP2000500006A (ja)	2000-01-11	百日咳菌の繁殖のための新規な方法
US3712944A (en)	1973-01-23	Stemlon and its production
CN115896039A (zh)	2023-04-04	一种利用片状载体培养工艺生产轮状病毒疫苗的方法
TWI690592B (zh)	2020-04-11	日本腦炎疫苗及其製備方法
CN106318992A (zh)	2017-01-11	利于多糖‑sph衍生物质量控制的工艺
SU301947A1 (ru)	1976-05-15	Способ получени антигенного комплекса брюшнотифозных бактерий
CN121555380A (zh)	2026-02-24	一株具有抗氧化作用的发酵粘液乳杆菌121及其应用